TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY

(19)

(11)

EP 2 701 737 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	01.05.2024 Bulletin 2024/18

(45)	Mention of the grant of the patent:
	27.03.2024 Bulletin 2024/13

(21)	Application number: 12777486.7

(22)	Date of filing: 27.04.2012

(51)

International Patent Classification (IPC):

A61K 39/35^(2006.01)
A61K 31/40^(2006.01)
A61K 9/16^(2006.01)
A61K 39/36^(2006.01)

A61K 31/44^(2006.01)
A61K 9/14^(2006.01)
A61P 37/00^(2006.01)
A61K 31/00^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 39/00; B82Y 5/00; A61K 2039/577; A61K 39/36; A61K 2039/55511; A61K 9/127; A61K 9/5146; A61K 38/38; A61K 2039/55555; A61K 47/6923; A61K 47/6929; A61K 47/6937; A61K 9/5115; A61K 38/13; A61K 38/1816; A61K 31/192; A61P 1/16; A61P 11/02; A61P 11/06; A61P 15/00; A61P 17/00; A61P 29/00; A61P 35/00; A61P 37/00; A61P 37/02; A61P 37/04; A61P 37/06; A61P 37/08; A61P 41/00; A61P 43/00; A61P 7/06; Y02A 50/30; A61K 2039/5154

	C-Sets:
	A61K 39/36, A61K 2300/00;

(86)	International application number:
	PCT/US2012/035383

(87)	International publication number:
	WO 2012/149268 (01.11.2012 Gazette 2012/44)

(54)	TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY SYNTHETISCHE TOLEROGENE NANOTRÄGER ZUR BEHANDLUNG VON ALLERGIEN NANOSUPPORTS SYNTHÉTIQUES TOLÉROGÈNES POUR THÉRAPIE D'UNE ALLERGIE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

29.04.2011 US 201161480946 P
29.07.2011 US 201161513514 P
06.09.2011 US 201161531153 P
06.09.2011 US 201161531215 P
06.09.2011 US 201161531147 P
06.09.2011 US 201161531175 P
06.09.2011 US 201161531209 P
06.09.2011 US 201161531168 P
06.09.2011 US 201161531204 P
06.09.2011 US 201161531194 P
06.09.2011 US 201161531164 P
06.09.2011 US 201161531180 P

(43)	Date of publication of application:
	05.03.2014 Bulletin 2014/10

(73)	Proprietor: Cartesian Therapeutics, Inc.
	Gaithersburg, MD 20878 (US)

(72)	Inventors:
	KISHIMOTO, Takashi, Kei Lexington, MA 02420 (US) FRASER, Christopher Arlington, MA 02476 (US) MALDONADO, Roberto, A. Jamaica Plain, MA 02130 (US)

(74)	Representative: EIP
	Fairfax House 15 Fulwood Place London WC1V 6HU London WC1V 6HU (GB)

(56)

References cited: :

WO-A1-99/22762
US-A1- 2008 031 899
US-A1- 2010 129 439
US-A1- 2010 151 000
US-A1- 2011 070 154

WO-A2-2010/138192
US-A1- 2010 129 392
US-A1- 2010 151 000
US-A1- 2010 233 251

TARZI MICHAEL ET AL: "Peptide immunotherapy for allergic disease", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON; GB, vol. 3, no. 4, 1 July 2003 (2003-07-01), pages 617-626, XP008096428, ISSN: 1471-2598, DOI: 10.1517/14712598.3.4.617
KARAMLOO FARIBA ET AL: "Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, vol. 35, no. 11, 1 November 2005 (2005-11-01), pages 3268-3276, XP002464627, ISSN: 0014-2980, DOI: 10.1002/EJI.200425522


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).